問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Veterans General Hospital (在職)

Division of Radiation Therapy

Division of Hematology & Oncology

Division of Urology

更新時間：2023-09-19

劉裕明Liu, Yu-Ming
  • Principal Investigator
  • Clinical Trial Experience (year) 17 years 10 個月

Recruiting Trial

2Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

劉裕明

List

8Cases

2015-12-01 - 2028-12-29

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated6Sites

馮思中
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2020-03-01 - 2032-06-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Not yet recruiting4Sites

Recruiting3Sites

2020-11-15 - 2028-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting5Sites

2023-06-03 - 2030-04-29

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Not yet recruiting3Sites

Recruiting1Sites

2025-02-03 - 2033-05-03

Phase II/III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2019-06-10 - 2024-04-24

Phase III

A Phase III, Randomized, Multi-Center, Double-Blind, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With and following Chemoradiotherapy Compared to Chemoradiotherapy Alone for Treatment in Women With Locally Advanced Cervical Cancer (CALLA)

  • Condition/Disease

    Locally Advanced Cervical Cancer

  • Test Drug

    Durvalumab

Participate Sites
6Sites

Terminated6Sites

2017-04-01 - 2023-10-31

Phase II/III

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Not yet recruiting1Sites

Recruiting1Sites

2012-09-03 - 2014-09-03

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Study ended1Sites

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB